With the advancement of available technologies in recent years, researchers are fast becoming aware of the advantages of using proteomics in their research to better understand human biology and disease and to drive pharmaceutical development towards new and improved therapies. Anders Mälarstig, the director of human genetics at Pfizer, came to this realization early on. While he began his research career using genetics to understand cardiovascular disease, he soon turned to proteomics, and specifically protein quantitative trait loci (pQTLs) to take his research one step further. In the following interview, Dr. Mälarstig makes the case for this proteogenomics approach to advance basic and clinical research and speaks to its advantages in the drug discovery and development space.
The National University of Singapore (NUS) Protein Biomarker Discovery Core Facility is one of the newest additions to the Olink core lab family. Established this year, the NUS Protein Biomarker Discovery Core Facility will offer full service of all Olink Target and Focus products, as well as Olink Explore. The core lab will focus on serving customers in Singapore and the Asia-Pacific region, where the demand for protein biomarker research has shot up in recent years. Lai Lai Yap, a senior laboratory manager in the NUS, describes their experience in becoming a certified core facility.
What makes for a successful Olink explore core lab partner? What type of training is involved, and how do the FAS team support and help core labs not just as they begin their core lab journey, but throughout their time as an Olink core lab partner? The following interview with Philippa Pettingill of the FAS team aims to answer such questions and more.
Olink’s core mission is ‘accelerating proteomics together’ with the scientific community. From the start, Olink has helped and supported countless researchers to carry out and advance their proteomics research using our PEA-based products and our team’s expertise.